top of page
Search

HepCure presentation at INHSU in 2022 in Glasgow, Scotland

Writer's picture: hepcurecahepcureca

HEPCURE™ HCV MODEL OF CARE – SUCCESSES AND LEARNINGS FROM OUR COLLECTIVE EFFORTS IN SCREENING AND LINKAGE TO CARE ACTIVITIES DURING THE COVID-19 PANDEMIC

Authors: Marcoux C1 , Fletcher D1 , Myles L1 , Saint Amour J1 , Eiloart S1 , Ymeri J1 , Greaves A1 , Fulop R1 , Reynolds L1 , Waithaka V1 , Hodgkinson E1 , Ngo H2


1. HepCURE™

2. Touro University – California, College of Pharmacy


Background: COVID-19 impacted HCV elimination programs worldwide. Suspension of HCV services and limited access has rendered engagement of the most marginalized patients particularly challenging.


Description of model of care/intervention: HepCURE™ is a Canadian non-profit established in 2019. Our multidisciplinary team consists of clinicians, nurses, phlebotomists, pharmacists and frontline workers. To maximize participation engagement, we offer “community-based” point-of-care testing and phlebotomy service, program incentives (meal vouchers, cell phones), SMS/phone appointment/adherence reminders, transportation, treatment delivery services and 24/7 telephone support. To address the challenges posed by the pandemic, we developed several initiatives:

- Three community-based clinics, and two mobile outreach units to screen participants in marginalized settings across 20 cities in Ontario

- Use of geo-mapping to identify 500+ social support programs accessed by marginalized people and 30+ pharmacies as partners to further support screening efforts and medication adherence

- HepCURE™ Patient Registry, an e-platform using informed verbal and/or photo consent to identify at-risk patients, ensure linkage to treatment and monitor their clinical progress in real-time


Effectiveness: Over 12 months (2/2021-2/2022), we screened 3243 participants; 67% were male. (46%, mobile units; 29%, community-based clinics; 22%, pharmacies). The number of HCV Ab+, diagnosed, undiagnosed, viremic, and linked to care patients are shown below.



• 40% (1312/3243) HCV Ab+

• 91% (1191/1312) Diagnosed (results shared with participants)

• 9% (121/1312) Undiagnosed (only completed point-of-care testing)

• 56% (738/1312) Confirmed viremia – HCV RNA+

• 80% (590/738) Linked to care (with HepCURE™, 540/590 – 92%)

• 20% (148/738) Not engaged with treatment

• 90% (485/540) Treated by HepCURE™

• 85% (411/485) Treatment completion


Conclusion and next steps: Our program was effective in diagnosing 91% of HCV Ab+ participants and linking 80% of treatmenteligible patients to care. We’ve implemented new workflow processes and programmatic changes to further improve patient retention. We’re currently replicating our program in another province to demonstrate feasibility of a countrywide elimination model.


Disclosure of Interest Statement: “HepCURE™ received grant funding from AbbVie Canada which was used in the development of its HCV Model of Care.”

2 views0 comments

Recent Posts

See All

Comments


We welcome you to share your valuable feedback

regarding our programs and services.

The sharing of your experience may lead to further improvements

and enhancements in patient care.

Email: info@hepcure.ca

Phone: 437-228-0751

Fax: 1-833-702-1234

© 2025 HepCURE

bottom of page